Drug Approval | August 19, 2022
Lupin receives approval from U.S. FDA for Rufinamide Tablets USP
The product will be manufactured at Lupin's facility in Goa, India.
The product will be manufactured at Lupin's facility in Goa, India.
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
The product will be manufactured at Lupin’s facility in Goa, India.
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Lupin is the 6th largest company in the Indian Pharmaceutical Market
he US FDA has issued six observations pursuant to the completion of the audit.
Subscribe To Our Newsletter & Stay Updated
